Immunocore Holdings plc Cash and Restricted Cash
Immunocore Holdings plc (IMCR) had Cash and Restricted Cash of $484.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $484.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $452.68M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $467.71M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $498.41M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $484.92M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $452.68M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $467.71M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $498.41M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $487.93M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $476.85M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $455.73M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $537.77M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $504.99M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $832.82M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $442.63M 10-K · filed 2026-02-25 |
| 2023-09-30 | $444.14M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $432.00M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $418.38M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $402.47M 10-K · filed 2026-02-25 |
| 2021-12-31 | $321.08M 10-K · filed 2025-02-26 |
| 2020-12-31 | $176.66M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |